Core Viewpoint - The company, Jiuzhitang, is actively engaged in the research and development of innovative drugs, including the anticoagulant YB209 and the antibiotic YB211, as well as stem cell projects [2] Group 1: R&D Projects - The YB209 project has completed the development and validation of methods for immunogenicity research, and has finished the closing of Phase I clinical trials [2] - The YB211 project has completed the preparation of clinical samples, conducted two stages of reproductive toxicity tests, initiated pharmacokinetics-pharmacodynamics (PK-PD) studies, and has fully launched Phase II clinical trials with subject enrollment [2] Group 2: Clinical Trials - The clinical trial for Jiuzhitang Meike's allogeneic bone marrow mesenchymal stem cell therapy for ischemic stroke has completed enrollment of all 45 subjects in Phase IIa [2] - The clinical trial for bone marrow mesenchymal stem cell injection for autoimmune pulmonary alveolar proteinosis has also completed enrollment of all 10 subjects [2] - A clinical trial for bone marrow mesenchymal stem cell injection for autism was initiated on August 26, 2025, following the kickoff meeting [2]